AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

Key Terms

atrial fibrillation (Afib) medical

An irregular, often fast heartbeat caused when the heart’s upper chambers lose their normal rhythm and quiver instead of pumping smoothly, like a drumbeat that skips and stumbles. It matters to investors because it increases the risk of stroke, hospitalization and long‑term treatment needs, driving demand for drugs, medical devices, monitoring services and insurance costs; outcomes of clinical trials or approvals can materially affect company value.

left atrial appendage (LAA) medical

The left atrial appendage (LAA) is a small, pouch-like structure on the left upper chamber of the heart where blood can stagnate and form clots, especially in people with irregular heartbeats. It matters to investors because medical devices, drugs, and procedures that close or treat the LAA aim to reduce stroke risk; their clinical trial results, regulatory approvals, and reimbursement decisions can drive market demand much like a safety feature that prevents a costly accident.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47^th Annual Global Health Care Conference.

AtriCure’s management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527069180/en/

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com

Marissa Bych
Gilmartin Group
Investor Relations
marissa@gilmartinir.com

Source: AtriCure, Inc.